Home » Biovail Seeks to Assure Investors Spooked by FDA Letter
Biovail Seeks to Assure Investors Spooked by FDA Letter
Biovail Corp. sought Monday to allay investor concerns over its announcement last week that its application for a new version of its antidepressant Wellbutrin XL had been rejected by the U.S. Food and Drug Administration.
Canada.com
Upcoming Events
-
25Apr
-
07May
-
14May
-
30May